The rapalogs everolimus and temsirolimus that inhibit mTOR signaling are used as antiproliferative drugs in several cancers. Here we investigated the influence of rapalogs-mediated immune modulation on their antitumor efficacy. Studies in metastatic renal cell carcinoma patients showed that everolimus promoted high expansion of FoxP 3 þ Helios þ Ki67 þ regulatory CD4 T cells (T regs ). In these patients, rapalogs strongly enhanced the suppressive functions of T regs , mainly in a contact-dependent manner. Paradoxically, a concurrent activation of spontaneous tumor-specific Th1 immunity also occurred. Furthermore, a high rate of Eomes þ CD8 þ T cells was detected in patients after a long-term mTOR inhibition. We found that early changes in the T regs /antitumor Th1 balance can differentially shape the treatment efficacy. Patients presenting a shift toward decreased T regs levels and high expansion of antitumor Th1 cells showed better clinical responses. Studies conducted in tumor-bearing mice confirmed the deleterious effect of rapalogs-induced T regs via a mechanism involving the inhibition of antitumor T-cell immunity. Consequently, the combination of temsirolimus plus CCR4 antagonist, a receptor highly expressed on rapalogs-exposed T regs , was more effective than monotherapy. Altogether, our results describe for the first time a dual impact of host adaptive antitumor T-cell immunity on the clinical effectiveness of rapalogs and prompt their association with immunotherapies.
Lang (2019) Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells, OncoImmunology, 8:4, e1560919,
BackgroundMultiple synergistic combination approaches with cancer drugs are developed to overcome primary resistance to immunotherapy; however, the mechanistic rationale to combine chemoradiotherapy (CRT) with immune checkpoint inhibitors remains elusive.MethodsThis study described the immunological landscape of tumor microenvironment (TME) exposed to CRT. Tumor samples from patients with rectal cancer (n=43) treated with neoadjuvant CRT or radiotherapy were analyzed by nanostring and immunohistochemistry. Studies in mice were performed using three syngeneic tumors (TC1, CT26 and MC38). Tumor-bearing mice were treated either with platinum-based CRT, radiotherapy or chemotherapy. Anti-CTLA-4 and/or anti-Programmed Cell Death Receptor-1 (PD-1) therapy was used in combination with CRT. The therapy-exposed TME was screened by RNA sequencing and flow cytometry and tumor-infiltrating T lymphocyte functionality was evaluated by interferon (IFN)-γ ELIspot and intracellular cytokine staining.ResultsFront-to-front comparison analysis revealed the synergistic effect of CRT to establish a highly inflamed and Th1-polarized immune signature in the TME of patients and mice. In both settings, CRT-exposed TMEs were highly enriched in newly-infiltrated tumor-specific CD8+ T cells as well as tissue resident memory CD103+CD8+ T cells. In mice, CD8 T cells were involved in the antitumor response mediated by CRT and were primed by CRT-activated CD103+ dendritic cells. In the three tumor models, we showed that concurrent combination of CRT with a dual CTLA-4 and PD-1 blockade was required to achieve an optimal antitumor effect and to establish a broad and long-lasting protective antitumor T cell immunity.ConclusionsOur results highlight the ability of CRT to stimulate strong antitumor T-cell-mediated immunity and tissue resident memory T activation in TME, to foster immune checkpoint inhibitors action. These findings have implications in clinic for the design clinical trials combining chemoradiation with immunotherapy.
Myeloid-derived suppressor cells (MDSC) promote immunosuppression and are a target in the field of immuno-oncology. Accumulation of MDSCs is associated with poor prognosis and resistance to immunotherapy for several cancers. Here, we describe an accumulation of a subset of circulating monocytic MDSCs (M-MDSC) overexpressing TIE2, the receptor for angiopoietin-2 (ANGPT2), in patients with non–small cell lung cancer (NSCLC). Greater numbers of circulating TIE2+ M-MDSCs were detected in patients with NSCLC compared with healthy subjects, and this accumulation correlated with ANGPT2 concentration in blood. The presence of an ANGPT2-rich environment was associated with impairment of preexisting T-cell responses against tumor-associated antigens (TAA) in patients with NSCLC. We demonstrated that ANGPT2 sensitizes TIE2+ M-MDSCs such that these cells suppress TAA-specific T cells. In patients with NSCLC, upregulation of the ANGPT2/TIE2+ M-MDSC signature in blood was associated with a poor prognosis. Our results identify the ANGPT2/TIE2+ M-MDSC axis as a participant in tumor immune evasion that should be taken into account in future cancer immunotherapy.
HLA-A*0201/DRB1*0101 transgenic mice (A2/DR1 mice) have been developed to study the
immunogenicity of tumor antigen-derived T cell epitopes. To extend the use and
application of this mouse model in the field of antitumor immunotherapy, we described
a tumor cell line generated from a naturally occurring tumor in A2/DR1 mouse named
SARC-L1. Histological and genes signature analysis supported the sarcoma origin of
this cell line. While SARC-L1 tumor cells lack HLA-DRB1*0101 expression, a very low
expression of HLA-A*0201 molecules was found on these cells. Furthermore they also
weakly but constitutively expressed the programmed death-ligand 1 (PD-L1).
Interestingly both HLA-A*0201 and PD-L1 expressions can be increased on SARC-L1 after
IFN-γ exposure in vitro. We also obtained two genetically
modified cell lines highly expressing either HLA-A*0201 or both HLA-A*0201/
HLA-DRB1*0101 molecules referred as SARC-A2 and SARC-A2DR1 respectively. All the
SARC-L1-derived cell lines induced aggressive subcutaneous tumors in A2DR1 mice
in vivo. The analysis of SARC-L1 tumor microenvironment revealed
a strong infiltration by T cells expressing inhibitory receptors such as PD-1 and
TIM-3. Finally, we found that SARC-L1 is sensitive to several drugs commonly used to
treat sarcoma and also susceptible to anti-PD-L1 monoclonal antibody therapy
in vivo. Collectively, we described a novel syngeneic tumor model
A2/DR1 mice that could be used as preclinical tool for the evaluation of antitumor
immunotherapies.
<div>Abstract<p>Myeloid-derived suppressor cells (MDSC) promote immunosuppression and are a target in the field of immuno-oncology. Accumulation of MDSCs is associated with poor prognosis and resistance to immunotherapy for several cancers. Here, we describe an accumulation of a subset of circulating monocytic MDSCs (M-MDSC) overexpressing TIE2, the receptor for angiopoietin-2 (ANGPT2), in patients with non–small cell lung cancer (NSCLC). Greater numbers of circulating TIE2<sup>+</sup> M-MDSCs were detected in patients with NSCLC compared with healthy subjects, and this accumulation correlated with ANGPT2 concentration in blood. The presence of an ANGPT2-rich environment was associated with impairment of preexisting T-cell responses against tumor-associated antigens (TAA) in patients with NSCLC. We demonstrated that ANGPT2 sensitizes TIE2<sup>+</sup> M-MDSCs such that these cells suppress TAA-specific T cells. In patients with NSCLC, upregulation of the ANGPT2/TIE2<sup>+</sup> M-MDSC signature in blood was associated with a poor prognosis. Our results identify the ANGPT2/TIE2<sup>+</sup> M-MDSC axis as a participant in tumor immune evasion that should be taken into account in future cancer immunotherapy.</p></div>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.